Loading...

FITC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6.7_FITC_102110
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
  • 53-6.7_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) FITC (filled histogram) or rat IgG2a, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100705 50 µg £21
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100706 500 µg £68
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed
  2. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  3. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  4. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
  5. Sun L, et al. 2021. Cancer Cell. :. PubMed
  6. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  7. Liu J, et al. 2019. Immunity. 50:600. PubMed
  8. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  9. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  10. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  11. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  12. Gerwing M, et al. 2020. Mol Imaging Biol. 1.959027778. PubMed
  13. Han X, et al. 2017. Int J Mol Sci. 10.3390/ijms18050942. PubMed
  14. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  15. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  16. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  17. Lin W, et al. 2020. Theranostics. 10:4871. PubMed
  18. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  19. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  20. Zhang J, et al. 2021. MedComm (Beijing). 2:256. PubMed
  21. Paschall A, et al. 2015. J Immunol. 194: 2369-2379. PubMed
  22. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  23. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  24. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  25. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  26. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  27. Wang Q, et al. 2020. Wound Repair Regen. 28:105. PubMed
  28. Castellanos CA, et al. 2021. Sci Immunol. 6:eabh0707. PubMed
  29. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  30. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  31. Hao B, et al. 2015. J Exp Med. 212:809. PubMed
  32. Apte S, et al. 2010. J Immunol. 185:998. PubMed
  33. Gotoh K et al. 2018. Cell reports. 25(7):1800-1815 . PubMed
  34. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  35. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  36. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  37. Wu K, et al. 2021. Aging (Albany NY). 13:. PubMed
  38. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  39. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  40. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  41. Morales D, et al. 2015. J Virol. 89:337. PubMed
  42. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  43. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  44. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  45. Wang X, et al. 2021. Front Cell Dev Biol. 632805:9. PubMed
  46. Luff DH, et al. 2021. Front Immunol. 631271:12. PubMed
  47. Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed
  48. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  49. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  50. Dodagatta-Marri E, et al. 2021. Cell Rep. 36:109309. PubMed
  51. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  52. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  53. Magod P, et al. 2021. Cell Reports. 36(5):109480. PubMed
  54. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  55. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  56. Artinger K, et al. 2015. PLoS One. 10: 0135087. PubMed
  57. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  58. DeBerge M, et al. 2013. PLoS One. 8:79340. PubMed
  59. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  60. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  61. MacDonald A, et al. 2021. Front Immunol. 12:755995. PubMed
  62. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  63. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  64. Velázquez K, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G699 - G712. PubMed
  65. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  66. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  67. Gu Y, et al. 2021. Cell Res. Online ahead of print. PubMed
  68. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  69. Wu J, et al. 2020. Immunity. 53:115. PubMed
  70. Köchl R, et al. 2020. Elife. 9:00. PubMed
  71. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  72. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  73. Xiao P, et al. 2019. J Exp Med. 216:337. PubMed
  74. Topper MJ et al. 2017. Cell. 171(6):1284-1300 . PubMed
  75. Li Y, et al. 2019. Sci Rep. 9:6932. PubMed
  76. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  77. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  78. Aebischer D, et al. 2014. PLoS One. 9:99297. PubMed
  79. Drees J, et al. 2015. Anticancer Res. 35:843. PubMed
  80. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  81. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  82. Li Y, et al. 2020. Cell Stem Cell. 27(5):732-747.e7. PubMed
  83. Crowe JL, et al. 2020. Proc Natl Acad Sci U S A. 22953:117. PubMed
  84. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  85. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  86. Srivastava S, et al. 2019. Cancer Cell. 35:489. PubMed
  87. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  88. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  89. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  90. Yang J, et al. 2020. Nature. 586:572. PubMed
  91. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  92. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  93. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  94. Wan X, et al. 2018. Nature. 560:107. PubMed
  95. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  96. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  97. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  98. Huang Z, et al. 2021. Nat Commun. 12:145. PubMed
  99. Grioni M, et al. 2021. Blood Adv. 5:2817. PubMed
  100. Matundan HH, et al. 2021. J Virol. 95:e0103621. PubMed
  101. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  102. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  103. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  104. Zheng D, et al. 2022. Acta Pharm Sin B. 12:2740. PubMed
  105. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  106. Nikolos F, et al. 2022. Nat Commun. 13:1487. PubMed
  107. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  108. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  109. Fang Y, et al. 2019. Aging (Albany NY). 11:4910. PubMed
  110. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  111. Du J, et al. 2018. AMB Express. 8:158. PubMed
  112. Holman P, et al. 2005. J Immunol. 174:3986. PubMed
  113. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  114. Jin C, et al. 2022. Oncoimmunology. 11:2099642. PubMed
  115. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  116. Daneshmandi S, et al. 2021. Elife. 10:. PubMed
  117. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  118. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  119. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  120. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  121. Li X, et al. 2020. Nat Commun. 4.877777778. PubMed
  122. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  123. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  124. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  125. Zhan L, et al. 2022. Cancer Lett. 529:37. PubMed
  126. Tsukui H, et al. 2020. BMC Cancer. 20:411. PubMed
  127. Wang L, et al. 2015. Cancer Immunol Res. 3: 1030-1041. PubMed
  128. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  129. Perry JL, et al. 2020. ACS Nano. 5.583333333. PubMed
  130. Blagih J, et al. 2020. Cell Rep. 30:481. PubMed
  131. Fu S, et al. 2020. Nat Commun. 0.7625. PubMed
  132. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  133. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  134. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  135. Riedl P, et al. 2009. J Immunol. 183:370. PubMed
  136. Feng D, et al. 2022. Nat Commun. 13:5554. PubMed
  137. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  138. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  139. Berghoff SA, et al. 2021. Nat Neurosci. 24:47. PubMed
  140. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  141. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  142. Kvell K, et al. 2014. Immunobiology. 219:644. PubMed
  143. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  144. Hu Z, et al. 2020. PLoS One. 15:e0228339. PubMed
  145. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  146. Wu P, et al. 2020. Cancer Immunol Res. 8:1470. PubMed
  147. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  148. Shen L, et al. 2015. Cancer Immunol Res. 3:136. PubMed
  149. Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed
  150. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  151. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  152. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  153. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  154. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  155. Urata S, et al. 2018. PLoS Pathog. 14:e1007172. PubMed
  156. Raju S, et al. 2020. Cell Reports. 29(9):2556-2564.e3.. PubMed
  157. Panigrahy D, et al. 2019. J Clin Invest. 130:2964. PubMed
  158. Li Q, et al. 2022. Front Oncol. 12:841977. PubMed
  159. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  160. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  161. Ren Y, et al. 2021. Nat Commun. 12:5405. PubMed
  162. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  163. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  164. Tsyklauri O, et al. 2021. EMBO Rep. 22:e50785. PubMed
  165. Petriv N, et al. 2021. Oncoimmunology. 10:1874159. PubMed
  166. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  167. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  168. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  169. Porrello A, et al. 2018. Nat Commun. 9:1988. PubMed
  170. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  171. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  172. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  173. Royzman D, et al. 2019. Front Immunol. 10:633. PubMed
  174. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  175. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  176. Li H, et al. 2022. iScience. 25:104481. PubMed
  177. Wang X, et al. 2022. Elife. 11:. PubMed
  178. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  179. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
  180. Li K, et al. 2020. Nat Commun. 0.795138889. PubMed
  181. Burton OT, et al. 2018. Clin Exp Allergy. 48:288. PubMed
  182. Wen X, et al. 2021. World J Gastroenterol. 27:2834. PubMed
  183. Wang K, et al. 2021. Nat Commun. 12:4558. PubMed
  184. D'Cruz L, et al. 2014. J Immunol. 192:2227. PubMed
  185. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  186. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  187. Su M, et al. 2018. Immunol Cell Biol. 9:2448. PubMed
  188. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  189. Tanegashima K et al. 2017. EBioMedicine. 24:247-256 . PubMed
  190. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  191. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  192. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  193. Ying B, et al. 2022. Sci Transl Med. 14:eabm3302. PubMed
  194. Lee S, et al. 2021. Autophagy. Online ahead of print. PubMed
  195. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  196. Akhtar MN, et al. 2020. PLoS Pathog. 16:e1009136. PubMed
  197. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  198. Gu Z, et al. 2021. Nat Genet. 53:672. PubMed
  199. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  200. Xie L, et al. 2020. Infect Immun. :88. PubMed
  201. Hayashi K, et al. 2020. Nat Commun. 4.832638889. PubMed
  202. Schlecker E, et al. 2012. J Immunol. 189:5602. PubMed
  203. Zhi Y, et al. 2020. Int J Mol Med. 45:1327. PubMed
  204. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
RRID
AB_312744 (BioLegend Cat. No. 100705)
AB_312745 (BioLegend Cat. No. 100706)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8a on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD8a

  • Biotin anti-mouse CD8a

  • FITC anti-mouse CD8a

  • PE anti-mouse CD8a

  • PE/Cyanine5 anti-mouse CD8a

  • Purified anti-mouse CD8a

  • PE/Cyanine7 anti-mouse CD8a

  • APC/Cyanine7 anti-mouse CD8a

  • Alexa Fluor® 488 anti-mouse CD8a

  • Alexa Fluor® 647 anti-mouse CD8a

  • Pacific Blue™ anti-mouse CD8a

  • Alexa Fluor® 700 anti-mouse CD8a

  • PerCP/Cyanine5.5 anti-mouse CD8a

  • PerCP anti-mouse CD8a

  • Brilliant Violet 421™ anti-mouse CD8a

  • Brilliant Violet 570™ anti-mouse CD8a

  • Brilliant Violet 650™ anti-mouse CD8a

  • Brilliant Violet 605™ anti-mouse CD8a

  • Ultra-LEAF™ Purified anti-mouse CD8a

  • Brilliant Violet 711™ anti-mouse CD8a

  • Brilliant Violet 785™ anti-mouse CD8a

  • Brilliant Violet 510™ anti-mouse CD8a

  • Purified anti-mouse CD8a (Maxpar® Ready)

  • Alexa Fluor® 594 anti-mouse CD8a

  • PE/Dazzle™ 594 anti-mouse CD8a

  • APC/Fire™ 750 anti-mouse CD8a

  • GoInVivo™ Purified anti-mouse CD8a

  • TotalSeq™-A0002 anti-mouse CD8a

  • Spark Blue™ 550 anti-mouse CD8a

  • Spark NIR™ 685 anti-mouse CD8a

  • TotalSeq™-C0002 anti-mouse CD8a

  • TotalSeq™-B0002 anti-mouse CD8a

  • Spark YG™ 570 anti-mouse CD8a

  • PE/Fire™ 640 anti-mouse CD8a

  • PE/Fire™ 700 anti-mouse CD8a

  • Spark Blue™ 574 anti-mouse CD8a Antibody

  • Spark Violet™ 423 anti-mouse CD8a Antibody

  • Spark UV™ 387 anti-mouse CD8a
ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account